A Study to Evaluate Renal Fibrosis Using MRI Techniques

  • STATUS
    Recruiting
  • End date
    Sep 1, 2024
  • participants needed
    15
  • sponsor
    Mayo Clinic
Updated on 29 October 2021
angiography
hypertension
antihypertensive drugs

Summary

The purpose of this study is to evaluate whether or not an MRI technique (quantitative magnetization transfer or qMT) in narrowing human kidneys is feasible, reproducible, and predicts recovery.

Description

Renal fibrosis is a final pathway and important biomarker of injury common to most forms of kidney disease. For example, in renal vascular disease (RVD) progressive renal fibrosis may induce kidney injury and hypertension. Early identification of fibrosis and adequate intervention may slow down renal disease progression, but adequate noninvasive strategies to detect and quantify renal fibrosis are yet to be identified.

Magnetization transfer imaging (MTI) magnetic resonance imaging (MRI) is a novel noninvasive method to evaluate the tissue macromolecular composition. The investigators have demonstrated that MTI can assess stenotic kidney fibrosis in murine and swine models of unilateral RVD. However, the clinical utility of MT-MRI to assess renal fibrosis is currently limited, because it is inherently semi-quantitative. In contrast, quantitative MT (qMT), based on biophysical compartment models, provides more objective measurement of tissue MT properties. A model fitting of MR signal acquired with various MT pulse amplitudes and offset frequencies, combined with scan-specific B0/B1/T1 maps, give rise to a more complete definition of tissue parameters, including a "bound pool fraction", a direct measure of the macromolecular content in tissue.

The hypothesis underlying this proposal is that qMT would reliably detect development of renal fibrosis at both 1.5 T and 3.0 T in subjects with RVD. To test this hypothesis, which is supported by strong preliminary data, the investigators will initially develop, optimize, and validate qMT for evaluation of fibrosis in the post-stenotic swine kidney. The investigators will correlate qMT-derived renal fibrosis with reference standards, as well as with single-kidney hemodynamics, function, and oxygenation, quantified using cutting-edge multi-detector CT (MDCT) and MRI techniques. The investigators will then determine the ability of qMT to predict renal recovery in pigs with RVD undergoing revascularization. Further, they will perform a pilot study to test the ability of qMT to quantify fibrosis in the post-stenotic human kidney, in comparison to innovative biomarkers of renal dysfunction and tissue damage.

Three specific aims will test the hypotheses: Specific Aim 1: qMT in stenotic swine kidneys is feasible, reliable, and reproducible at 1.5 and 3.0 T. Specific Aim 2: qMT predicts renal recovery potential in response to percutaneous transluminal renal angioplasty (PTRA). Specific Aim 3: qMT in stenotic human kidneys is feasible, reproducible, and predicts recovery.

The proposed studies may therefore establish a reliable, noninvasive, and clinically feasible strategy to quantify kidney fibrosis, a key biomarker for renal outcomes and therapeutic success.

Details
Condition arterial hypertension, Diabetes and Hypertension, High Blood Pressure (Hypertension - Pediatric), Elevated Blood Pressure, Hypertension, Vascular Diseases, High Blood Pressure (Hypertension), renovascular, high blood pressure
Treatment qMT-MRI to detect fibrosis.
Clinical Study IdentifierNCT04508049
SponsorMayo Clinic
Last Modified on29 October 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Between ages 40 and 80 years old
Patients with hypertension (BP>140/90 mmHg) and/or requirement for two or more antihypertensive medications for more than 4 weeks
Serum creatinine under 2.2 and 2.0 mg/dL for men and women, respectively (Caucasians). Values for African-American subjects are slightly higher (2.4 mg/dL, males; 2.1 mg/dL females)
No contraindications to angiography: severe contrast allergy
No contraindications to no-contrast MR evaluations: e.g. pacemaker or magnetically active metal fragments, claustrophobia
Patients have the ability to comply with protocol
Patients are competent and able to provide written informed consent

Exclusion Criteria

Patient has serum creatinine >2.2 mg/dL for men and >2.0 mg/dL for women (Caucasians); >2.4 mg/dL for men and >2.1 mg/dL for women (African American)
RVD in a solitary kidney
Patients have clinically significant medical conditions within the prior six months: e.g. myocardial infarction, congestive heart failure, stroke, that would, in the opinion of the investigators, compromise the safety of the patient
Uncontrolled hypertension (Systolic BP >180 mmHg despite therapy)
Diabetes requiring insulin or oral hypoglycemic medications
Evidence of hepatitis B or C, or HIV infection
Requirement for potentially nephrotoxic drugs; e.g., non-steroidal anti-inflammatory drugs
Cardiac ejection fraction less than 30%
History of deep venous thrombosis within 3 months of enrollment
Kidney transplant
Pacemaker, implantable defibrillator or other contraindication to MRI
Inability to comply with breath-hold for 20 seconds
Any active malignancy and undergoing therapy
Patients are pregnant
Kidney or ureteric stone
Another known acute or chronic kidney disease
Federal medical center inmates
Latex allergy
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note